MediGene AG - Product Pipeline Review - 2016

Published: Sep, 2016 | Pages: 42 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

MediGene AG - Product Pipeline Review - 2016

Summary

Global Markets Direct's, 'MediGene AG - Product Pipeline Review - 2016', provides an overview of the MediGene AG's pharmaceutical research and development focus. 

The report provides comprehensive information on the therapeutics under development by MediGene AG, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the pipeline therapeutic landscape of MediGene AG
- The report provides overview of MediGene AG including its business description, key facts, and locations and subsidiaries
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report assesses MediGene AG's pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report features MediGene AG's out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons To Buy

- Evaluate MediGene AG's strategic position with total access to detailed information on its product pipeline
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for MediGene AG
- Identify potential new clients or partners in the target demographic
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding MediGene AG's pipeline depth and focus of pipeline therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

 Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 4
MediGene AG Snapshot 5
MediGene AG Overview 5
Key Facts 5
MediGene AG - Research and Development Overview 6
Key Therapeutic Areas 6
MediGene AG - Pipeline Review 9
Pipeline Products by Stage of Development 9
Pipeline Products - Monotherapy 10
Pipeline Products - Out-Licensed Products 11
Out-Licensed Products/Combination Treatment Modalities 12
MediGene AG - Pipeline Products Glance 13
MediGene AG - Late Stage Pipeline Products 13
Phase III Products/Combination Treatment Modalities 13
MediGene AG - Clinical Stage Pipeline Products 14
Phase II Products/Combination Treatment Modalities 14
Phase I Products/Combination Treatment Modalities 15
MediGene AG - Early Stage Pipeline Products 16
Preclinical Products/Combination Treatment Modalities 16
Discovery Products/Combination Treatment Modalities 17
MediGene AG - Unknown Stage Pipeline Products 18
Unknown Products/Combination Treatment Modalities 18
MediGene AG - Drug Profiles 19
Cellular Immunotherapy 1 for Oncology - Drug Profile 19
Product Description 19
Mechanism Of Action 19
R&D Progress 19
Cellular Immunotherapy 2 for Oncology - Drug Profile 20
Product Description 20
Mechanism Of Action 20
R&D Progress 20
Cellular Immunotherapy for Acute Myeloblastic Leukemia - Drug Profile 21
Product Description 21
Mechanism Of Action 21
R&D Progress 21
Cellular Immunotherapy for Multiple Myeloma - Drug Profile 23
Product Description 23
Mechanism Of Action 23
R&D Progress 23
Cellular Immunotherapy for Oncology - Drug Profile 24
Product Description 24
Mechanism Of Action 24
R&D Progress 24
Cellular Immunotherapy to Target hTERT and Survivin for Prostate Cancer - Drug Profile 25
Product Description 25
Mechanism Of Action 25
R&D Progress 25
Cellular Immunotherapy to Target MAGE-A1 for Multiple Myeloma - Drug Profile 27
Product Description 27
Mechanism Of Action 27
R&D Progress 27
Cellular Immunotherapy to Target Opa-Interacting Protein 4 and Wilm's Tumor 1 for Acute Myeloblastic Leukemia - Drug Profile 28
Product Description 28
Mechanism Of Action 28
R&D Progress 28
human papillomavirus [serotypes 16, 31] (virus like particle) vaccine - Drug Profile 29
Product Description 29
Mechanism Of Action 29
R&D Progress 29
Monoclonal Antibodies to Target TCR for Autoimmune Disease and T-Cell Leukemia - Drug Profile 30
Product Description 30
Mechanism Of Action 30
R&D Progress 30
RhuDex - Drug Profile 31
Product Description 31
Mechanism Of Action 31
R&D Progress 31
sinecatechins - Drug Profile 33
Product Description 33
Mechanism Of Action 33
R&D Progress 33
MediGene AG - Pipeline Analysis 34
MediGene AG - Pipeline Products by Target 34
MediGene AG - Pipeline Products by Route of Administration 35
MediGene AG - Pipeline Products by Molecule Type 36
MediGene AG - Pipeline Products by Mechanism of Action 37
MediGene AG - Dormant Projects 38
MediGene AG - Discontinued Pipeline Products 39
Discontinued Pipeline Product Profiles 39
etomoxir 39
Monoclonal Antibody for Ovarian Cancer 39
MediGene AG - Locations And Subsidiaries 40
Head Office 40
Other Locations & Subsidiaries 40

Appendix 41
Methodology 41
Coverage 41
Secondary Research 41
Primary Research 41
Expert Panel Validation 41
Contact Us 41
Disclaimer 42

List of Tables

MediGene AG, Key Facts 5
MediGene AG - Pipeline by Indication, 2016 8
MediGene AG - Pipeline by Stage of Development, 2016 9
MediGene AG - Monotherapy Products in Pipeline, 2016 10
MediGene AG - Out-Licensed Products in Pipeline, 2016 11
MediGene AG - Out-Licensed Products/ Combination Treatment Modalities, 2016 12
MediGene AG - Phase III, 2016 13
MediGene AG - Phase II, 2016 14
MediGene AG - Phase I, 2016 15
MediGene AG - Preclinical, 2016 16
MediGene AG - Discovery, 2016 17
MediGene AG - Unknown, 2016 18
MediGene AG - Pipeline by Target, 2016 34
MediGene AG - Pipeline by Route of Administration, 2016 35
MediGene AG - Pipeline by Molecule Type, 2016 36
MediGene AG - Pipeline Products by Mechanism of Action, 2016 37
MediGene AG - Dormant Developmental Projects,2016 38
MediGene AG - Discontinued Pipeline Products, 2016 39
MediGene AG, Subsidiaries 40